ethyl ester of 3-(3-indolyl)butyric acid | 67996-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl ester of 3-(3-indolyl)butyric acid
• 英文别名: ethyl β-methyl-1H-indole-3-propionate；ethyl 3-(1H-indol-3-yl)butanoate；ethyl 3-(1H-indol-3-yl)bytanoate；ethyl 3-(3-indolyl)butyrate；3-(3-indolyl)butyrate；ethyl 3-(3-indolyl)-butyrate
• CAS: 67996-15-0
• 化学式: C₁₄H₁₇NO₂
• mdl: MFCD28118658
• 分子量: 231.294
• InChiKey: DOABEWVYDYLWIK-UHFFFAOYSA-N

物化性质

• 沸点：
  179-181 °C(Press: 2 Torr)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl ester of 3-(3-indolyl)butyric acid 在 对甲苯磺酸 正丁基锂 、 sodium hydride 、 二异丙胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 7.5h， 生成 tert-butyl 2-hydroxy-4-methyl-1,1-bismethylthio-1,2,3,4-tetrahydrocarbazole-2-acetate
  参考文献：
  名称：

  Reactions and synthetic applications of .BETA.-keto sulfoxides. X. Synthesis of ellipticine analogs modified at the 5-position.

  摘要：

  乙基吲哚丁酸（11）和甲基甲基硫代甲基亚砜（MMTS）衍生的β-酮亚砜（12）在p-甲苯磺酸（TsOH）的作用下环化为4-甲基-1,1-双甲基硫代-2-氧代-1,2,3,4-四氢咔唑（13）。在羰基上

  DOI：

  10.1248/cpb.29.1606
• 作为产物：
  描述：

  5-<1-(1H-indol-3-yl)ethyl>-2,2-dimethyl-1,3-dioxane-4,6-dione 在 铜 作用下， 以 吡啶 、 乙醇 为溶剂， 反应 3.0h， 以0.38 g的产率得到ethyl ester of 3-(3-indolyl)butyric acid
  参考文献：
  名称：

  CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF

  摘要：

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防和治疗可以通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其他疾病和状况中找到应用。

  公开号：

  US20150158860A1

文献信息

• CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150158860A1

  公开（公告）日：2015-06-11

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防和治疗可以通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其他疾病和状况中找到应用。
• [EN] CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMIDE CYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE ET UTILISATIONS DE CEUX-CI
  申请人：CONNEXIOS LIFE SCIENCES PVT LTD

  公开号：WO2013128465A1

  公开（公告）日：2013-09-06

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，本发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将用于治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其它疾病和状况。
• [EN] DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF<br/>[FR] DÉRIVÉS D'AZA-ADAMANTANE ET LEURS UTILISATIONS
  申请人：CONNEXIOS LIFE SCIENCES PVT LTD

  公开号：WO2013111150A1

  公开（公告）日：2013-08-01

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可以通过抑制该酶而预防或治疗的某些疾病方面具有用处。此外，本发明涉及这些化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、糖耐量受损、脂质紊乱如血脂异常、高血压以及其他疾病和病症的治疗中发挥作用。
• DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150141650A1

  公开（公告）日：2015-05-21

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可以通过抑制该酶而预防或治疗的某些疾病方面具有用处。此外，本发明涉及这些化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、糖耐量受损、脂质紊乱如血脂异常、高血压以及其他疾病和病症的治疗中发挥作用。
• Alkylidene malonates and α,β-unsaturated α′-hydroxyketones as practical substrates for vinylogous Friedel–Crafts alkylations in water catalysed by scandium(<scp>iii</scp>) triflate/SDS
  作者：Jens Oelerich、Gerard Roelfes

  DOI：10.1039/c4ob02487g

  日期：——

  Alkylidene malonates and α,β-unsaturated α′-hydroxyketones are demonstrated to be efficient classes of electrophiles for the scandium(III) triflate/sodium dodecyl sulphate (SDS) catalysed vinylogous Friedel–Crafts alkylation of indoles and pyrroles in water. These substrates contain an easily removable auxiliary group that increases affinity for the catalytic metal ion in such a way that they can compete

  已证明亚炔基丙二酸酯和α，β-不饱和α'-羟基酮是三氟甲磺酸（（III）/十二烷基硫酸钠（SDS）催化水中的吲哚和吡咯的乙烯基弗里德尔-克拉夫特烷基化反应的有效亲电试剂。这些底物包含易于除去的辅助基团，其以与水竞争与催化金属离子结合的方式增加了对催化金属离子的亲和力。因此，亚烷基丙二酸酯和α，β-不饱和α'-羟基酮是例如以下的有吸引力的替代品，α，β-不饱和羧酸和-酯，它们在水性介质中在这些反应中反应性不足。与有机溶剂相比，路易斯酸和SDS在催化中的结合可显着加速水中的反应。提出的方法是有吸引力的，因为反应快速，实验上简单并且产生了高产率的产物。